The FiREwORK Trial - Self-management With FootweaR Combined With Exercise for OsteoaRthritis (OA) at the Knee: a Phase II Randomized Controlled Trial
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 97
- 试验地点
- 1
- 主要终点
- Change in severity of knee pain on walking
研究概览
简要总结
Osteoarthritis (OA) is a chronic degenerative joint disease and leading cause of musculoskeletal pain and disability worldwide. The high rates of knee replacement surgery worldwide emphasize the need for more effective non-surgical interventions to attenuate progressive disability. International scientific and professional societies also propose that therapies need to seek efficacious combinations of modalities with the ultimate aim to achieve longer-term, optimal and synergistic treatment effects.
Exercise therapy, such as strengthening and aerobic exercise, is universally, and strongly, recommended as it demonstrates beneficial effects on clinical symptoms and is considered safe for all patients with knee OA. However, during activities as simple as walking, higher knee joint loads have been demonstrated in people with medial tibiofemoral OA, a common form of knee OA. Increased joint loading as such may elicit aggravated symptoms and accelerated joint structural decline over time. No convincing evidence exists to confirm exercise therapy effectively alters joint loading parameters during walking gait in people with knee OA. Notably, recent studies suggest that wearing appropriate footwear may help offload the joint in people with knee OA, a strategy that is also easily applicable at a wide population level.
The purpose of this clinical study is to compare 9-month treatment consisting of exercise therapy and daily wear of one of two shoe classes (flat flexible shoes or stable supportive shoes), on symptom relief and joint structural damage in people with knee OA. In this study, we will randomly allocate eligible participants in one of two treatment arms. This means there will be an equal amount of participants in each group, and participants nor researchers will be able to choose in which group participants will end up in.Participants in both groups will enroll in a 9 month exercise program and will be provided a pair of one of the two shoe classes to wear daily. To ensure an unbiased appraisal of treatment effects, we will not disclose the study hypotheses to participants during the intervention period.
The results of this study will help determine whether the addition of appropriate footwear to exercise therapy improves symptom relief and/or slows structural disease progression in people with knee OA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 50 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Symptomatic and radiographic diagnosis of knee OA as per the American College of Rheumatology criteria (ie, aged≥50, knee pain on most days and osteophytes)
- •Radiographic evidence of medial OA (ie, Kellgren Lawrence(KL) grade ≥2, ≥grade 1 medial joint space narrowing (JSN) (scale 0-3)> lateral JSN, using a standardized atlas)
- •Average knee pain on walking over the past week of ≥4 on a 11-point numeric rating scale (NRS; "0=no pain" to "10=worst pain imaginable")
- •Ability to walk unaided
- •Willing to comply with therapy prescriptions
- •Sufficient understanding of the Dutch language
排除标准
- •Current and previous (3 months) participation in exercise therapy
- •Current and previous (3 months) use of customised footwear, minimalist shoes, insoles, braces and unable/unwilling to abandon during the study
- •Knee surgery in either knee and/or injections (corticosteroids, hyaluronic acid) in the study knee (most painful knee or right knee if both equally painful) in the past 6 months
- •Current or recent (4 weeks) use of oral corticosteroids
- •Knee replacement or high tibial osteotomy surgery in the past, or planned during the study
- •Inflammatory arthropathies
- •Other muscular, joint, neurological or metabolic conditions affecting lower limb function and/or precluding safe regular participation in exercise therapy and walking
- •Body mass index (BMI) of >36 kg/m2 (due to difficulties performing gait analysis and MRI)
- •Foot/ankle pain/pathologies at either side, and worse than knee pain complaints
- •Contra-indications for radiography & MRI
- •Use of supplements (eg, glucosamine, chondroitin, curcuma derivates) or pain medication (NSAIDs, paracetamol) or other disease modifying or anti-bone resorptive drugs if participants were not on a stable dose for ≥2 months prior to entering the trial
研究组 & 干预措施
Flat Flexible Shoes+Exercise Therapy
This arm will wear Flat Flexible Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
干预措施: Flat Flexible Shoes (Device)
Flat Flexible Shoes+Exercise Therapy
This arm will wear Flat Flexible Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
干预措施: Exercise Therapy (Other)
Stable Supportive Shoes+Exercise Therapy
This arm will wear Stable Supportive Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
干预措施: Exercise Therapy (Other)
Stable Supportive Shoes+Exercise Therapy
This arm will wear Stable Supportive Shoes daily for the duration of 9 months combined with supervised facility-based and home-based exercise therapy (months 0-3) and unsupervised home-based exercise therapy (months 4-9).
干预措施: Stable Supportive Shoes (Device)
结局指标
主要结局
Change in severity of knee pain on walking
时间窗: Measured at baseline, 13 and 37 weeks
Scored on an 11-point numeric rating scale for average knee pain on walking over the past week, with terminal descriptors of "0=no pain" to "10=worst pain imaginable".
次要结局
- Severity of intercondylar synovitis(Measured at baseline, 13 and 37 weeks)
- Severity of bone marrow lesions(Measured at baseline, 13 and 37 weeks)
- Severity of whole knee effusion(Measured at baseline, 13 and 37 weeks)
- Severity of physical dysfunction(Measured at baseline, 13 and 37 weeks)
- Participant-perceived global change in pain(Measured at 13 and 37 weeks)
- Participant-perceived global change in physical function(Measured at 13 and 37 weeks)
- Participant-perceived global change overall(Measured at 13 and 37 weeks)
- Average Daily Step Count(Measured during weeks 1, 12 and 36)
- Habitual physical activity level(Measured at baseline, 13 and 37 weeks)
- Severity of knee pain overall(Measured at baseline, 13 and 37 weeks)
- Health-related quality of life(Measured at baseline, 13 and 37 weeks)
